DK2429317T4 - Sammensætninger med højt indhold af omega-3-fedtsyrer og med lavt indhold af phytansyre - Google Patents

Sammensætninger med højt indhold af omega-3-fedtsyrer og med lavt indhold af phytansyre Download PDF

Info

Publication number: DK2429317T4
Authority: DK; Denmark
Prior art keywords: omega; compositions; fatty acids; phytic acid; levels
Prior art date: 2009-04-17

Application number

DK09776547.3T

Other languages

English (en)

Other versions

DK2429317T3 (da

Inventor

Lopez Jose Manuel Cela

Original Assignee

Natac Pharma S L

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-17

Filing date

2009-04-17

Publication date

2019-05-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41279300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2429317(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-04-17 Application filed by Natac Pharma S L filed Critical Natac Pharma S L

2016-07-18 Application granted granted Critical

2016-07-18 Publication of DK2429317T3 publication Critical patent/DK2429317T3/da

2019-05-13 Publication of DK2429317T4 publication Critical patent/DK2429317T4/da

Links

IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 title 1
IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 title 1
239000000203 mixture Substances 0.000 title 1
235000020660 omega-3 fatty acid Nutrition 0.000 title 1
229940012843 omega-3 fatty acid Drugs 0.000 title 1
239000006014 omega-3 oil Substances 0.000 title 1
229940068041 phytic acid Drugs 0.000 title 1
235000002949 phytic acid Nutrition 0.000 title 1
239000000467 phytic acid Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
- C11C1/02—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils
- C11C1/025—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils by saponification and release of fatty acids
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
- C11C1/08—Refining
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/02—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with glycerol
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oil, Petroleum & Natural Gas (AREA)
Ophthalmology & Optometry (AREA)
Wood Science & Technology (AREA)
Physical Education & Sports Medicine (AREA)
Nutrition Science (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Microbiology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Food Science & Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Polymers & Plastics (AREA)
Neurology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)
Obesity (AREA)

DK09776547.3T 2009-04-17 2009-04-17 Sammensætninger med højt indhold af omega-3-fedtsyrer og med lavt indhold af phytansyre DK2429317T4 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP2009/002842 WO2010118761A1 (en)	2009-04-17	2009-04-17	Compositions rich in omega-3 fatty acids with a low content in phytanic acid

Publications (2)

Publication Number	Publication Date
DK2429317T3 DK2429317T3 (da)	2016-07-18
DK2429317T4 true DK2429317T4 (da)	2019-05-13

Family

ID=41279300

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK09776547.3T DK2429317T4 (da)	2009-04-17	2009-04-17	Sammensætninger med højt indhold af omega-3-fedtsyrer og med lavt indhold af phytansyre

Country Status (14)

Country	Link
US (1)	US9062275B2 (da)
EP (1)	EP2429317B2 (da)
JP (1)	JP5872453B2 (da)
KR (1)	KR101759353B1 (da)
CN (1)	CN102438468B (da)
AU (1)	AU2009344374B2 (da)
BR (1)	BRPI0924012A2 (da)
CA (1)	CA2756528A1 (da)
DK (1)	DK2429317T4 (da)
ES (1)	ES2574136T5 (da)
MX (1)	MX2011010821A (da)
PL (1)	PL2429317T5 (da)
PT (1)	PT2429317T (da)
WO (1)	WO2010118761A1 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012067224A1 (ja) *	2010-11-19	2012-05-24	日本水産株式会社	角膜上皮障害及び／又は結膜上皮障害の治療又は予防剤
ES2828479T3 (es)	2011-01-25	2021-05-26	Nestle Sa	Métodos y composiciones para tratar, reducir o prevenir el deterioro del sistema visual de los animales
US20120252888A1 (en) *	2011-03-29	2012-10-04	Palupa Medical Ltd.	Compositions and Methods for Treating Neurologic Disorders
CN102747045B (zh) *	2011-04-19	2013-12-18	华中农业大学	一种猪流感h1n1亚型灭活疫苗及制备方法
WO2013037794A1 (en)	2011-09-12	2013-03-21	Georgiou Tassos	Use of omega fatty acids for treating disease
RS57777B1 (sr)	2012-01-06	2018-12-31	Omthera Pharmaceuticals Inc	Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
US9480651B2 (en)	2012-03-30	2016-11-01	Sancilio & Company, Inc.	Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US20160228397A1 (en)	2012-03-30	2016-08-11	Sancilio & Company, Inc.	Omega-3 fatty acid ester compositions
US10898458B2 (en)	2012-03-30	2021-01-26	Micelle Biopharma, Inc.	Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
JP6359517B2 (ja)	2012-03-30	2018-07-18	サンシリオアンドカンパニー, インコーポレイテッドSancilio & Company, Inc.	ω−３脂肪酸エステル組成物
EP2846779A4 (en)	2012-05-07	2015-12-16	Omthera Pharmaceuticals Inc	STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS
AU2013314303B2 (en)	2012-09-12	2018-01-18	Novaliq Gmbh	Semifluorinated alkane compositions
CN113679699B (zh)	2012-09-12	2022-10-28	诺瓦利克有限责任公司	包含半氟化烷烃的混合物的组合物
WO2014085486A2 (en)	2012-11-30	2014-06-05	Waters Technologies Corporation	Methods and apparatus for the analysis of vitamin d metabolites
ITMI20130354A1 (it)	2013-03-08	2014-09-09	Again Life Italia Srl	Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
EP2956056B1 (en)	2013-03-14	2019-06-05	Universite Laval	Electroretinography (erg) system for the assessment of psychiatric disorders
WO2014143806A1 (en) *	2013-03-15	2014-09-18	The Penn State Research Foundation	Acid stable liposomal compositions
US9877944B2 (en) *	2013-04-22	2018-01-30	Smartfish As	Use of a composition comprising fish oil and juice for the treatment and/or post treatment of cancer
EP3062788A1 (en) *	2013-10-28	2016-09-07	Nestec S.A.	Monoacylglycerols and fat-soluble nutrients for use in the treatment of malabsorption having a non-mechanical basis
EP2881456A1 (en) *	2013-12-04	2015-06-10	Natac Pharma, S.L.	Enzymatic method for separating phytanic acid from fats or oils containing it and recovering unaltered products free of phytanic acid
MX390909B (es) *	2013-12-19	2025-03-21	Tassos Georgiou	Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.
AU2015229240B9 (en) *	2014-03-13	2019-05-02	Biojiva Llc	Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
WO2015165507A1 (en) *	2014-04-29	2015-11-05	Georgiou Tassos	Treatment of eye diseases using omega 3 fatty acids and aa/epa blood ratio
JP2016141624A (ja) *	2015-01-30	2016-08-08	有限会社ハヌマット	癌患者の予後改善剤
CN107666904B (zh)	2015-03-26	2022-02-01	提贝托·布鲁泽塞	多不饱和脂肪酸的纯化组合物、其制备方法及其用途
EP3345986A4 (en) *	2015-08-31	2019-05-01	Nippon Suisan Kaisha, Ltd.	COMPOSITION WITH FREE MULTIPLE UNSATURATED FATTY ACIDS AND MANUFACTURING METHOD THEREFOR
CN110403923B (zh)	2015-09-30	2021-09-21	诺瓦利克有限责任公司	半氟化化合物和其组合物
JPWO2017094804A1 (ja) *	2015-12-01	2018-09-13	日本水産株式会社	ドコサヘキサエン酸含有油及びその製造方法
WO2017160869A1 (en) *	2016-03-15	2017-09-21	Biomerica, Inc.	Compositions, devices, and methods of fibromyalgia sensitivity testing
KR20180051737A (ko) *	2016-11-08	2018-05-17	차의과학대학교 산학협력단	대장염-관련 암 발생을 줄이는 ω-3 폴리불포화지방산 활성 성분으로 포함하는 항암 조성물
RU2652342C1 (ru) *	2017-07-13	2018-04-25	Наталья Александровна Гаврилова	Композиция для лечения ретинальной неоваскуляризации в эксперименте и способ лечения с ее использованием
WO2019068763A1 (en)	2017-10-04	2019-04-11	Novaliq Gmbh	OPHTHALMIC COMPOSITIONS COMPRISING F6H8
CN108096181A (zh) *	2018-02-05	2018-06-01	西安医学院	Dha、epa在制备治疗干眼症的口服药物的应用
CN112153970A (zh)	2018-04-27	2020-12-29	诺瓦利克有限责任公司	用于治疗青光眼的包含他氟前列素的眼用组合物
SG11202102820VA (en)	2018-10-12	2021-04-29	Novaliq Gmbh	Ophthalmic composition for treatment of dry eye disease
JP7608707B2 (ja) *	2019-02-25	2025-01-07	株式会社坪田ラボ	近視進行抑制剤、機能性食品及び眼科用組成物
SG10201902000YA (en) *	2019-03-06	2020-10-29	Nat Univ Singapore	Isthmin 1 for treatment of lung inflammation
KR20210016746A (ko)	2019-08-05	2021-02-17	충남대학교산학협력단	오메가-3 불포화 지방산을 포함하는 항톡소포자충 조성물
JP2022544847A (ja) *	2019-08-21	2022-10-21	バークアンドボイヤー、インコーポレイテッド	一価不飽和脂肪酸組成物及び脂肪性肝疾患を治療するための使用
CN110846346B (zh) *	2019-11-26	2021-06-22	瞿瀚鹏	富含Sn-2位DHA的微生物油脂及其制备方法和应用
US12115005B2 (en)	2020-03-26	2024-10-15	Diamentis Inc.	Systems and methods for processing retinal signal data and identifying conditions
KR20210018171A (ko)	2020-11-16	2021-02-17	충남대학교산학협력단	오메가-3 지방산으로의 전환을 유도하는 Caenorhabditis elegans fat-1효소를 포함하는 항톡소포자충 조성물
WO2022170226A1 (en) *	2021-02-08	2022-08-11	Synaptogenix, Inc.	Treatment of optic nerve inflammation using pkc activators
CN113584093B (zh) *	2021-07-30	2022-07-19	江南大学	一种高dha含量的结构脂质的制备方法及其产品
CN113995747A (zh) *	2021-10-19	2022-02-01	杭州莱樱斯生物医药科技有限公司	一种治疗脱发的产品及银杏内酯a在治疗应激诱发脱发的新用途
AU2023219254A1 (en)	2022-02-09	2024-08-01	Diamentis Inc.	Systems and methods for retinal stimulation and/or collecting retinal signal data
KR102925130B1 (ko)	2022-12-13	2026-02-13	충남대학교산학협력단	노빌레틴을 유효성분으로 하는 톡소포자충 감염증의 예방 또는 치료용 조성물

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5697503A (en) *	1980-01-07	1981-08-06	Nippon Oil & Fats Co Ltd	Separation of constituent component from mixed composition of plural component of org. compound
JPS57149400A (en) *	1981-03-12	1982-09-14	Kureha Chemical Ind Co Ltd	Manufacture of high purity long chain highly unsaturated fatty acid ester
EP0347509A1 (en)	1988-06-21	1989-12-27	Century Laboratories Inc.	A process of extraction and purification of polyunsaturated fatty acids from natural sources
US4792418A (en) *	1985-08-14	1988-12-20	Century Laboratories, Inc.	Method of extraction and purification of polyunsaturated fatty acids from natural sources
IT1205043B (it)	1987-05-28	1989-03-10	Innova Di Ridolfi Flora & C S	Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
US4843095A (en)	1987-08-07	1989-06-27	Century Laboratories, Inc.	Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
US4874629A (en)	1988-05-02	1989-10-17	Chang Stephen S	Purification of fish oil
US5023100A (en)	1988-05-02	1991-06-11	Kabi Vitrum Ab	Fish oil
JPH0225447A (ja) *	1988-07-13	1990-01-26	Nippon Oil & Fats Co Ltd	高度不飽和脂肪酸類の製造方法
GB8819110D0 (en)	1988-08-11	1988-09-14	Norsk Hydro As	Antihypertensive drug & method for production
DK190689D0 (da)	1989-04-19	1989-04-19	Novo Industri As	Omestringsproces
US5013569A (en)	1990-05-21	1991-05-07	Century Laboratories, Inc.	Infant formula
SE9303446D0 (sv)	1993-10-20	1993-10-20	Trikonex Ab	A novel urea fractionation process
CN1105205A (zh)	1994-01-11	1995-07-19	黄升	富含dha和活性钙的补脑益智营养食品及其制备方法
DK0682006T3 (da)	1994-05-09	1999-10-18	Nestle Sa	Fremgangsmåde til fremstilling af et koncentrat af estere af flerumættede fede syrer
JPH0898659A (ja)	1994-09-30	1996-04-16	Nippon Suisan Kaisha Ltd	ストレスに対する改善効果を有する魚類用飼料
CN1130040A (zh)	1995-12-05	1996-09-04	杨学斌	一种含dha的健脑膨化食品
GB2350610A (en)	1999-06-01	2000-12-06	Jfs Envirohealth Ltd	Preparation of pure unsaturated fatty acids
CA2311974A1 (en)	1999-06-28	2000-12-28	Nisshin Flour Milling Co., Ltd.	Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters
US7226916B1 (en) *	2000-05-08	2007-06-05	N.V. Nutricia	Preparation for the prevention and/or treatment of vascular disorders
JP4530311B2 (ja) †	2000-07-13	2010-08-25	日本水産株式会社	リパーゼを用いたグリセライドの製造方法
CN1345544A (zh) *	2000-09-29	2002-04-24	国家海洋药物工程技术研究中心	海洋产物营养保健蛋的生产方法
NL1019368C2 (nl) *	2001-11-14	2003-05-20	Nutricia Nv	Preparaat voor het verbeteren van receptorwerking.
CN1378846A (zh) *	2002-03-22	2002-11-13	海南加华海产生物制药有限公司	鲨鱼肝油胶丸
JP4771697B2 (ja) *	2002-09-24	2011-09-14	サントリーホールディングス株式会社	認知能力の正常応答の低下予防、改善又は向上作用を有する組成物
US6846942B2 (en)	2003-05-20	2005-01-25	David Rubin	Method for preparing pure EPA and pure DHA
CN1245169C (zh)	2004-01-29	2006-03-15	任连坤	一种提高记忆力、改善认知的纯天然复合制剂及其制备方法
CN101018862B (zh) *	2004-04-22	2013-10-09	联邦科学技术研究组织	用重组细胞合成长链多不饱和脂肪酸
BRPI0516803A (pt) *	2004-11-19	2008-09-23	Martek Biosciences Corp	oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
CN101213281B (zh) *	2005-05-04	2013-03-13	普罗诺瓦生物医药挪威公司	新的dha衍生物及其作为药物的用途
BRPI0613358A8 (pt) *	2005-07-08	2017-12-26	Dsm Ip Assets Bv	ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
ITMI20051560A1 (it) *	2005-08-10	2007-02-11	Tiberio Bruzzese	Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
US20070166411A1 (en) *	2005-12-16	2007-07-19	Bristol-Myers Squibb Company	Nutritional supplement containing long-chain polyunsaturated fatty acids
ES2277557B1 (es)	2005-12-21	2008-07-01	Proyecto Empresarial Brudy, S.L.	Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
US9265745B2 (en) *	2005-12-21	2016-02-23	Brudy Technology S.L.	Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
JP2009526033A (ja) *	2006-02-07	2009-07-16	オメガトリエーエス	オメガ３
US8003813B2 (en) *	2006-06-27	2011-08-23	Pos Pilot Plant Corporation	Process for separating saturated and unsaturated fatty acids
US7550614B2 (en)	2006-11-13	2009-06-23	Rohm And Haas Company	Method for esterification of free fatty acids in triglycerides
KR100832397B1 (ko) *	2007-02-12	2008-05-26	경북대학교 산학협력단	디아실글리세롤함유 식용유지의 제조방법
CN100574772C (zh) *	2007-03-23	2009-12-30	童宥霖	一种含叶黄素的软胶囊及其制备方法
US20080268117A1 (en)	2007-04-30	2008-10-30	David Rubin	Method of purifying oils containing epa and dha
WO2009020406A1 (en) *	2007-08-07	2009-02-12	Granate Seed Limited	Methods of making lipid substances, lipid substances made thereby and uses thereof
CN101381298B (zh) *	2008-10-21	2011-09-07	四川省毛叶山桐子科技股份有限公司	利用毛叶山桐子油制备共轭亚油酸的方法
WO2011018096A1 (en) *	2009-08-10	2011-02-17	K.D. Pharma Bexbach Gmbh	Phytanic acid fractionation process, fatty acid products and use thereof

2009
- 2009-04-17 DK DK09776547.3T patent/DK2429317T4/da active
- 2009-04-17 WO PCT/EP2009/002842 patent/WO2010118761A1/en not_active Ceased
- 2009-04-17 EP EP09776547.3A patent/EP2429317B2/en active Active
- 2009-04-17 AU AU2009344374A patent/AU2009344374B2/en active Active
- 2009-04-17 MX MX2011010821A patent/MX2011010821A/es active IP Right Grant
- 2009-04-17 US US13/264,659 patent/US9062275B2/en active Active
- 2009-04-17 JP JP2012505054A patent/JP5872453B2/ja active Active
- 2009-04-17 ES ES09776547T patent/ES2574136T5/es active Active
- 2009-04-17 BR BRPI0924012A patent/BRPI0924012A2/pt not_active IP Right Cessation
- 2009-04-17 CN CN200980158786.7A patent/CN102438468B/zh active Active
- 2009-04-17 PT PT97765473T patent/PT2429317T/pt unknown
- 2009-04-17 PL PL09776547T patent/PL2429317T5/pl unknown
- 2009-04-17 CA CA2756528A patent/CA2756528A1/en not_active Abandoned
- 2009-04-17 KR KR1020117027108A patent/KR101759353B1/ko active Active

Also Published As

Publication number	Publication date
US9062275B2 (en)	2015-06-23
EP2429317A1 (en)	2012-03-21
AU2009344374B2 (en)	2015-07-23
EP2429317B2 (en)	2019-02-20
JP2012523823A (ja)	2012-10-11
CN102438468B (zh)	2014-06-04
PL2429317T5 (pl)	2019-09-30
WO2010118761A1 (en)	2010-10-21
EP2429317B1 (en)	2016-03-30
KR20120039521A (ko)	2012-04-25
US20120053242A1 (en)	2012-03-01
MX2011010821A (es)	2012-01-20
AU2009344374A1 (en)	2011-10-27
PL2429317T3 (pl)	2016-09-30
ES2574136T5 (es)	2019-08-30
DK2429317T3 (da)	2016-07-18
CN102438468A (zh)	2012-05-02
ES2574136T3 (es)	2016-06-15
JP5872453B2 (ja)	2016-03-01
BRPI0924012A2 (pt)	2019-09-24
KR101759353B1 (ko)	2017-07-18
PT2429317T (pt)	2016-07-22
CA2756528A1 (en)	2010-10-21

Publication	Publication Date	Title
DK2429317T4 (da)	2019-05-13	Sammensætninger med højt indhold af omega-3-fedtsyrer og med lavt indhold af phytansyre
DK3037089T3 (da)	2020-01-20	Eicosapentaensyreethylester til behandling af hypertriglyceridæmi
EP2448433A4 (en)	2013-01-02	ENRICHED DRINKS WITH OMEGA-3 FATTY ACIDS
EP2433630A4 (en)	2014-01-08	SELF-EMULSIFIABLE COMPOSITION OF FATTY ACID 3
EP2498602A4 (en)	2014-05-21	STABILIZED FORMULATIONS FROM FATTY ACIDS
ZA201308469B (en)	2015-08-26	Nutritional compositions including branched chain fatty acids and methods of using same
AP3549A (en)	2016-01-15	Glycerides and fatty acid mixtures and methods of using same
EP2515946A4 (en)	2015-10-07	NANOCONJUGATE AND NANOCONJUGATE FORMULATIONS
BR112012017831A2 (pt)	2015-10-06	micro-organismos produtores de ácido eicosapentaenóico, composições e ácido graxo e método de fabricação e uso dos mesmos
DK2339925T3 (da)	2022-10-31	Fødevaresammensætninger af mikroalgebiomasse
ZA201107517B (en)	2012-06-27	Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
EP2846779A4 (en)	2015-12-16	STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS
IL228516A (en)	2017-12-31	A compound for oral administration containing an omega-3 fatty acid ester and rosovastatin
EP2408299A4 (en)	2012-08-15	FATTY ACID MONOGLYCERIDE COMPOSITIONS
PL2633009T3 (pl)	2016-10-31	Niewodny środek smarny i kompozycje paliwowe zawierające estry kwasów tłuszczowych kwasów hydroksykarboksylowych, i ich zastosowania
ZA201108657B (en)	2013-01-30	Isoxazolines as inhibitors of fatty acid amide hydrolase
ZA201403784B (en)	2015-09-30	Compositions comprising 20-carbon fatty acids and methods of making and using same
EP2448431A4 (en)	2014-12-31	BARRIER COMPOSITIONS AND OVEN-COOKED FOOD ENRICHED WITH OMEGA-3 FATTY ACID
ZA201302760B (en)	2014-12-23	Novel omega-3 and omega-6 fatty acid compositions and uses thereof
IL219659A0 (en)	2012-07-31	Azocyclic inhibitors of fatty acid amide hydrolase
EP2512268A4 (en)	2013-11-27	MEAT COMPOSITION ENHANCED WITH OMEGA-3 FATTY ACID
DK2588420T3 (da)	2020-10-12	Kedelstensfjernelse af oxalater med syresammensætninger
DK3826630T3 (da)	2022-09-26	Sammensætninger af cannabinoider med polyumættede fedtsyremonoglycerider og anvendelser heraf
FR2948025B1 (fr)	2013-01-11	Composition comprenant un polyphenol et un acide gras omega-3
AP2831A (en)	2014-01-31	Production of fatty acid and fatty acid ester